Phaeosynt is a biotechnology company that produces animal-free antibodies using microalgae and diatomaceous earth.
Phaeosynt has raised $1.8M in total funding. The most recent round was Seed. The last funding was announced in February 2025.
Phaeosynt's investors include NBank, Susanna Zapreva, PSD Bank Braunschweig, FONDE Ventures.
Phaeosynt is headquartered in Hanover, Germany.
Phaeosynt is a biotechnology company that produces animal-free antibodies using microalgae and diatomaceous earth.
Phaeosynt is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Phaeosynt — Funding & Investors." VCBacked, February 12, 2025, https://www.vcbacked.co/company/phaeosynt. Accessed August 14, 2026.
VCBacked. (2025). Phaeosynt — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/phaeosynt
{{cite web |title=Phaeosynt — Funding & Investors |url=https://www.vcbacked.co/company/phaeosynt |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated